Clincosm LogoSign in Get a demo

MOCA-2: MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?

Sponsor
Centre Francois Baclesse (Other)
Overall Status
Recruiting
CT.gov ID
NCT03299855
Collaborator
UCOG (Unite de coordination en Onco-Gériatrie) (Other)
110
Enrollment
6
Locations
71.6
Anticipated Duration (Months)
18.3
Patients Per Site
0.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study concerns elderly patients with cancer with onco-geriatric assessment.

This study propose to associate the collection of the results with the Mini-Cog and the CODEX with the passing of the MoCA and the MMS tests, as well as a neuropsychological assessment, in order to determine if the patients have cognitive impairments, to evaluate the sensitivity of these 4 screening tests in elderly patients seeking treatment for their cancer. The results of this study will make it possible, where appropriate, to adapt the practice in the context of oncogeriatric assessment.

Condition or Disease Intervention/Treatment Phase
  • Other: Passation of neuropsychological test
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
110 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Passation of MMS and MoCA tests associated to passation of neuropsychological testPassation of MMS and MoCA tests associated to passation of neuropsychological test
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?
Actual Study Start Date :
Oct 13, 2017
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Evaluate the sensitivity of MoCA test [Up 2 months after inclusion, before initiation of treatment]

    MoCA is considered clinically relevant if its sensitivity to identify patients with cognitive impairment is at least 75%

Eligibility Criteria

Criteria

Ages Eligible for Study:
70 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Patient aged over 70 years

  • Patient with cancer (solid tumor or haemopathy) for whom a first line treatment is envisaged (whatever it is). Surgery and radiotherapy are allowed before entry into the study.

  • Patient candidate for oncogeriatric assessment

  • Patient agree to participate in the study

  • Using the French language

Exclusion Criteria:

  • Primary central nervous system or cerebral metastasis

  • Evolutionary psychiatric pathology known (e.g. schizophrenia)

  • Severe Visual and / or Auditory Impairment

  • Patients unable to respond to cognitive tests

  • Patient (s) deprived of liberty, under guardianship or curatorship

  • Refusal of participation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre François Baclesse Caen France
2 CHU Caen France
3 CH Cherbourg France
4 Ch Compiegne Compiègne France
5 Centre Henri Becquerel Rouen France
6 Centre Hospitalier Saint-Lô France

Sponsors and Collaborators

  • Centre Francois Baclesse
  • UCOG (Unite de coordination en Onco-Gériatrie)

Investigators

  • Principal Investigator: florence JOLY, PhD, Centre François Baclesse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Francois Baclesse
ClinicalTrials.gov Identifier:
NCT03299855
Other Study ID Numbers:
  • 2017-A01079-44
First Posted:
Oct 3, 2017
Last Update Posted:
Mar 29, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Francois Baclesse
oncogeriatric
MMS
MoCA
Additional relevant MeSH terms:
Cognition Disorders

Study Results

No Results Posted as of Mar 29, 2022